Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-L1 x TIGIT bispecific antibody (Cellemedy)
- Development stage
- Preclinical
- Lead developer
- Cellemedy
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The PD-L1 x TIGIT bispecific antibody is an investigational immunotherapy being developed by Cellemedy. It is designed to simultaneously target and block two distinct immune checkpoint pathways: the Programmed Death-Ligand 1 (PD-L1) / PD-1 axis and the T-cell Immunoreceptor with Ig and ITIM domains (TIGIT) pathway. PD-L1 is often overexpressed on tumor cells to evade immune detection, while TIGIT is an inhibitory receptor found on T cells and Natural Killer (NK) cells that further suppresses the immune response. By co-inhibiting these targets, this bispecific antibody aims to synergistically restore the activity of exhausted immune cells and promote a more robust anti-tumor response compared to monotherapy.
- Other names
- PD-L1/TIGIT bispecific antibodyCellemedy PD-L1 x TIGIT bispecific antibody
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on PD-L1 x TIGIT bispecific antibody (Cellemedy).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-L1 x TIGIT bispecific antibody (Cellemedy).